marijuana stocks news

Abattis Legal Action Goes From Federal to Washington State Court

Vancouver, BC / ACCESSWIRE / November 10, 2014 / Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (ATTBF) (CSE:ATT), wishes to advise its shareholders that end of day Friday November 7th the company filed its suit in King County Superior Court, that it had previously filed in Federal court. It was filed end of day Friday. The hearing on it’s motion for a temporary restraining order is scheduled Monday at 1:30 pm.

Now that the company has made its filing in Washington State Court and will have its case heard in a jurisdiction where a decision to issue a temporary restraining order can be made if deemed appropriate by the court.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD

“Mike Withrow”
Michael Withrow, President & CEO

For further information, contact the Company’s Investor Relations, Saf Dhillon at (604) 336.0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

SOURCE: Abattis Bioceuticals Corp.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Organigram Holdings Inc. (OGRMF) reports impressive growth for 2018 in advance of adult recreational sales results

Organigram reports impressive growth for 2018 in advance of adult recreational sales…

Verano Holdings Corp. (VRNOF) Announces First Quarter 2022 Financial Results

Verano Announces First Quarter 2022 Financial Results Verano Holdings Corp. (CSE: VRNO)…

mCig Inc., (MCIG) Grow Contractors Division Exceeds Entire Q4 2017 Revenues

MCIG’s Grow Contractors Division Exceeds Entire Q4 2017 Revenues in the First…